



ZIOPHARM Oncology, Inc.
Investor Relations Department
One First Ave., Parris Building, # 34
Navy Yard Plaza
Boston, MA 02199
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	3.68
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.33 - 7.88
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 13, 2018

[Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1](#)

Feb 12, 2018

[Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond](#)

Feb 6, 2018

[Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance](#)

Jan 9, 2018

[Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference](#)

Dec 21, 2017

[ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Upcoming Events [\[View all \]](#)

Mar 1, 2018 4:30 PM ET

[ZIOPHARM 4Q17 Earnings Call](#)

Financials [\[View all \]](#)

Feb 16, 2017

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017

[Quarterly Report \(10-Q\)](#)

Jul 31, 2017

[Quarterly Report \(10-Q\)](#)

May 1, 2017

[Quarterly Report \(10-Q\)](#)